BCL2 and Hepatic fibrosis: Consistent with the histological evidence, Venetoclax also reduced the hydroxyproline content in the miR-122 KO livers by ~50% (Figure 5H), underscoring the significance of BCL2 in mediating liver fibrosis and the therapeutic efficacy of Venetoclax in vivo.